Product Description
Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Head and Neck Cancer|Chronic Lymphoid Leukemia|Prolymphocytic Leukemia|Prolymphocytic B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Immunoblastic Lymphadenopathy|Large-Cell Anaplastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Mantle-Cell Lymphoma|Leukemia, Plasma Cell|Mycosis Fungoides|Adult T-Cell Leukemia-Lymphoma|Thromboembolism|Pancreatic Cancer|Diffuse Large B-Cell Lymphoma|Squamous Cell Carcinoma|Endometrial Cancer|Adenocarcinoma|Acute Myeloid Leukemia|Kidney Cancer|Acute Monocytic Leukemia|Multiple Myeloma|Acute Myelomonocytic Leukemia|Preleukemia|Sezary Syndrome|Melanoma|Renal Cell Carcinoma|T-Cell Cutaneous Lymphoma|Ovarian Cancer|Peritoneal Cancer|Follicular Lymphoma|Multiple Sclerosis|Breast Cancer|Waldenstrom Macroglobulinemia|Lymphomatoid Granulomatosis|Prostate Cancer|B-Cell Marginal Zone Lymphoma|Sarcoma|Esophageal Cancer|Myelodysplastic Syndrome|Hypereosinophilic Syndrome|Acute Erythroblastic Leukemia|Lymphoma, B-Cell|Acute Megakaryoblastic Leukemia|Acute Basophilic Leukemia|Acute Eosinophilic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Seminoma|Liver Cancer|Testicular Cancer|Germinoma|Gastrointestinal Cancer
Phase 1: Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Brain Stem Cancer|Kidney Cancer|Medulloblastoma|Wilms Tumor|Neuroblastoma|Gastrointestinal Stromal Tumors|Acute Erythroblastic Leukemia|Breast Cancer|Melanoma|Chronic Lymphoid Leukemia|Oncology Solid Tumor Unspecified|Liver Cancer|Primitive Neuroectodermal Tumors|Thrombocytopenia|Non-Small-Cell Lung Cancer|Embryonal Rhabdomyosarcoma|Lymphoma, Non-Hodgkin|Sarcoma|Blast Crisis|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Basophilic Leukemia|Lymphoma, B-Cell|Acute Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Hypereosinophilic Syndrome|Acute Eosinophilic Leukemia|Prolymphocytic B-Cell Leukemia|Optic Nerve Cancer|Optic Nerve Glioma|Soft Tissue Cancer|Lymphoid Leukemia|Cerebellar Cancer|Osteosarcoma|Oncology Hematological Unspecified|Peripheral Neuroectodermal Tumors, Primitive|Mantle-Cell Lymphoma|Retinoblastoma|Sarcoma, Ewing|Ependymoma|Astrocytoma|Hypothalamic Cancer|Kidney Diseases|Supratentorial Cancer|Pancreatic Cancer|Mesothelioma|Anemia, Refractory|Prostate Cancer|Skin Cancer|Adenocarcinoma|Prolymphocytic Leukemia|Lymphoproliferative Disorders|Esophageal Cancer|Leukemia|B-Cell Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|Male Breast Cancer|Hairy Cell Leukemia|Lymphoma|Intestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TPI-ALV-102 | P2 |
Terminated |
Myelodysplastic Syndrome|Preleukemia |
2021-08-16 |
|
| TPI-ALV-202 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-04-22 |
|
| M16-186 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-01-25 |
41% |
| NCI-2020-05266 | P2 |
Withdrawn |
Acute Myeloid Leukemia |
2020-10-12 |